APR 21, 2019 10:20 PM PDT

Type 2 Diabetic Drug Reverses Heart Failure

WRITTEN BY: Nouran Amin

In a study published in the Journal of American Cardiology, a drug used for the treatment of diabetes—empagliflozin—was shown to improve the hearts function by reversing the progression of heart failure in non-diabetic animal models.

"This drug could be a promising treatment for heart failure in both non-diabetic and diabetic patients," said lead author Juan Badimon, MD, Professor of Cardiology and Director of the Atherothrombosis Research Unit at the Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. "Our research can lead to a potential application in humans, save lives, and improve quality of life."

Learn more about how diabetes is related to heart disease:

In diabetes, empagliflozin limits renal sugar resorption in individuals with Type 2 diabetes. Past studies have confirmed that these patients that take empagliflozin don't commonly develop heart failure despite having a higher risk due to their diabetes. These studies led researchers to wonder if the drug exerts action independent of anti-diabetic activity that is implicated in heart failure prevention.

Researchers found that the drug reversed heart failure by improving cardiac metabolism—producing more energy and function more strongly and efficiently.

"This study confirmed our hypothesis that empagliflozin is an incredibly effective treatment for heart failure and not only an antidiabetic drug. Moreover, this study demonstrated that empagliflozin is useful for heart failure independently of a patient's diabetic status. Importantly, empagliflozin switches cardiac metabolism toward fatty acid and ketone body consumption, thus allowing the production of more energy in the heart," explained co-lead author Carlos Santos-Gallego, MD, postdoctoral fellow at the Icahn School of Medicine at Mount Sinai. "Empagliflozin may be a potentially effective treatment for heart failure patients. This is extremely important because heart failure is a disease with a mortality above 50 percent at 5 years. This study offers a new therapeutic strategy in heart failure, something badly needed given that there have not been new effective drugs for heart failure since the 1990s."

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 07, 2019
Drug Discovery
JAN 07, 2019
First-in-Human Trial of Senolytic Drugs
According to a study published in the journal EBioMedicine, the very first results on the treatment of a deadly age-related disease in human patients using...
JAN 23, 2019
Drug Discovery
JAN 23, 2019
Frequent Aspirin Use Can Lead to Increased Bleeding
According to a systemic study published in the Journal of the American Medical Association (JAMA), taking aspirin regularly may prevent heart attacks and s...
FEB 04, 2019
Microbiology
FEB 04, 2019
Potential New Antibiotic is Made by an Insect-linked Microbe
Like many other organisms, bacteria have to compete for resources and have developed a wide array of strategies to use, including antibiotics....
MAR 10, 2019
Drug Discovery
MAR 10, 2019
Can Green Tea Reverse Memory Impairment?
In a study published in the Journal of Biological Chemistry, a diet containing green tea and carrots reversed Alzheimer's-like symptoms in mice that ar...
MAR 18, 2019
Cell & Molecular Biology
MAR 18, 2019
Antifungal Drug May Bring Relief to CF Patients
Cystic fibrosis affects around 700,000 people worldwide. New research has found a potential treatment for patients that don't respond to current therapies....
APR 22, 2019
Drug Discovery
APR 22, 2019
New Oral Drug for Multiple Sclerosis Treatment
The U.S. Food and Drug Administration has approved a new oral drug for the treatment of multiple sclerosis (MS)--a chronic, inflammatory, autoimmune diseas...
Loading Comments...